NCT01588678已完成1 期
A Phase 1, Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose
研究概览
简要总结
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
详细描述
This is a Phase 1, open-label study of DS-3078a to assess safety and tolerability, identify the maximum tolerated dose (MTD) and tentative recommended phase 2 dose (RP2D), and assess pharmacokinetic and pharmacodynamic properties in subjects with advanced solid tumor malignancies or lymphomas. The study will include 2 parts: Dose Escalation and Dose Expansion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A pathologically or cytologically documented advanced solid tumor or lymphoma that has relapsed from or is refractory to standard treatment or for which no standard treatment is available.
- •Men or women >=18 years old.
- •Eastern Cooperative Oncology Group (ECOG) performance status =<1
- •Have adequate bone marrow function, defined as:
- •Platelet count >=100 x 10^9/L for solid tumors and >=75 x 10^9/L for lymphomas,
- •Hemoglobin level >=9.0 g/dL, and ANC >=1.5 x 10^9/L for solid tumors and >=1.0 x 10^9/L for lymphomas.
- •Have adequate renal function, defined as:
- •Creatinine clearance >=60 mL/min, or creatinine =<1.5 x ULN.
- •Have adequate hepatic function, defined as:
- •AST/ALT levels =<3 x ULN (=<5 x ULN if liver metastases are present) and
- •Bilirubin =<1.5 x ULN.
- •Have adequate blood clotting function, defined as prothrombin time and activated partial thromboplastin time =<1.5 x ULN.
- •Subjects must be fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects) and must sign and date an Institutional Review Board/Ethics Committee-approved informed consent form (including Health Insurance Portability and Accountability Act authorization, if applicable) before performance of any study specific procedures or tests.
- •A pathologically or cytologically documented advanced solid tumor or non-Hodgkin lymphoma, with measurable disease based on RECIST 1.1 or revised IWG criteria, that is refractory to standard treatment. The solid tumor types that will be included in the study are of the following kinds in which the mTOR signaling is frequently activated: endometrial, prostate, breast, gastric, cervical,ovarian, or neuroendocrine cancers, soft-tissue sarcoma, squamous cell NSCLC,renal cell carcinoma or other tumor types approved by the Sponsor.
- •Agree to undergo pre- and post-treatment tumor biopsies.
排除标准
- •History of primary central nervous system malignancies
- •Gastrointestinal diseases that could affect the absorption of DS-3078a in the opinion of the Investigator
- •Subjects with a fasting glucose >126 mg/dL (>7 mmol/L)
- •History of diabetes mellitus (type 1 or 2) or glycosylated hemoglobin >7.0% at screening
- •Positive test for hepatitis B surface antigen or hepatitis C antibody
- •Recipient of live vaccine within 1 month of or during study drug treatment
- •Use of chronic systemic corticosteroids (use of nasal or inhaled steroids is permitted)
- •Subjects requiring daily supplemental oxygen
- •Recipient of an allogenic stem cell or bone marrow transplant
- •Presence of a concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator or Sponsor
- •Clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms.
- •Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE v4 grade =<1 or baseline.
- •Systemic treatment with anticancer therapy, antibody-based therapy, retinoid therapy, or hormonal therapy within 3 weeks before study drug treatment; or treatment with nitrosoureas or mitomycin C within 6 weeks before study drug treatment; or treatment with small-molecule targeted agents within 2 weeks or 5 half-lives before study drug treatment, whichever is longer.
- •Therapeutic radiation or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment
- •Participation in a clinical study within 3 weeks (2 weeks or 5 half-lives, whichever is longer, for small-molecule targeted agents) before study drug treatment, or current participation in other investigational procedures
- •Concomitant treatment with strong inhibitors or inducers of cytochrome P450 3A4 and P glycoprotein
- •Less than 1 week since using systemically acting drugs that increase gastric pH, such as H2-blockers and proton pump inhibitors. Antacids should be avoided within 48 hours of the first dose of DS 3078a
- •Prolongation of corrected QT interval by Fridericia's method (QTcF) at rest, where the mean QTcF interval is >450 msec based on triplicate electrocardiogram (ECG)
- •Pregnant or breastfeeding
- •Substance abuse or medical, psychological, or social conditions that, in the opinion of the Investigator, may interfere with the subject's participation in the clinical study or evaluation of the clinical study results
- •Subjects who have had prior treatment with an mTOR catalytic site inhibitor or dual PI3K/mTOR inhibitor (including, but not limited to, OSI-027, INK128, ADZ8055,AZD2014, WYE12513, PP242, BEZ-235, DS-7423, XL765, GDC-0980, SF1126, GSK2126458, PF4691502, and PF05212384) will be disqualified from entering the study.
研究组 & 干预措施
DS-3078a
Experimental
Part 1 - Dose escalation of DS-3078a to determine the maximum tolerated dose (MTD) will be guided by the modified continuous reassessment method (mCRM) using a Bayesian logistic regression model (BLRM) following escalation with overdose control (EWOC) principle.
Before starting mCRM, initial dose escalation will proceed following an accelerated titration in which single subjects will be enrolled into sequential dose levels with a dose increment of up to 100% from the previous dose.
Upon completion of Part 1 with established MTD and tentative recommended phase 2 dose (RP2D), the Dose Expansion (Part 2) will begin with the intention of further assessing the safety and tolerability of DS-3078a, confirming the RP2D, determining the Pharmacodynamic response in tumor samples, and evaluating preliminary efficacy of DS-3078a in subjects.
干预措施: DS-3078a (Drug)
结局指标
主要结局
Maximum tolerated dose
时间窗: 3 years
To determine the maximum tolerated dose (MTD) and tentative recommended Phase 2 dose (RP2D) of DS 3078a
次要结局
- assess pharmacodynamic effects tumor glucose uptake(3 years)
- determine the terminal half-life of DS 3078a(3 years)
- effect on glucose metabolism(3 years)
- assess tumor response(3 years)
- determine the AUC of DS 3078a(3 years)
- determine the Tmax of DS 3078a(3 years)
- determine the Cmax profile of DS 3078a(3 years)
- assess pharmacodynamic effects v-akt murine thymoma viral oncogene(3 years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05537987InnoCare Pharma Inc.30
终止
1 期
Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid TumorsTumorsNCT00105170Biogen13
终止
1 期
Study of ADCT-301 in Patients With Selected Advanced Solid TumorsHead and Neck Cancer Squamous Cell CarcinomaGastric CancerNon-small Cell Lung CancerPancreas CancerColo-rectal CancerFallopian Tube CancerOvarian CancerMelanomaEsophageal CancerTriple-negative Breast CancerRenal Cell CarcinomaBladder CancerNCT03621982ADC Therapeutics S.A.78
终止
1 期
Dose-escalation Study of Birinapant and Pembrolizumab in Solid TumorsSolid TumorsNCT02587962Medivir34
已完成
1 期
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors PatientsAdvanced/Metastatic Solid TumorsNCT04501276Adagene Inc72